What is Valencell?
Valencell is a specialized innovator in the digital health sector, focusing on the development of intuitive solutions for chronic disease management. The company is particularly recognized for its advancements in hypertension monitoring, highlighted by the development of a cuffless, lightweight blood pressure measuring device. With a formidable intellectual property portfolio exceeding 150 patents, Valencell integrates sophisticated biometric sensor technology with advanced analytics. This technological foundation enables users to track health trends via mobile applications, facilitating proactive health management and empowering individuals to maintain healthier lifestyles through data-driven insights.
How much funding has Valencell raised?
Valencell has raised a total of $38.6M across 8 funding rounds:
Series B
$5.5M
Series C
$7M
Private Equity
$2.6M
Series D
$11M
Series E
$10.5M
Debt
$350K
Debt
$647K
Series B (2011): $5.5M led by TDF Ventures and True Ventures
Series C (2014): $7M supported by TDF Ventures and True Ventures
Private Equity (2015): $2.6M, investors not publicly disclosed
Series D (2016): $11M backed by WSJ Joshua Fund, TDF Ventures, and GII Tech
Series E (2018): $10.5M with participation from GII LLC, WSJ Joshua Fund, TDF Ventures, and Sonion a/s
Debt (2020): $350K led by PPP
Debt (2021): $647K supported by PPP
Key Investors in Valencell
TDF Ventures
An early-stage venture capital firm based in Chevy Chase, Maryland, specializing in enterprise-focused infrastructure, software, and services.
True Ventures
A founder-first venture capital firm that provides strategic guidance and capital to early-stage technology and artificial intelligence companies.
WSJ Joshua Fund
An institutional investor participating in the strategic financing rounds to support the advancement of biometric sensor technology.
What's next for Valencell?
With the recent influx of capital, Valencell is well-positioned to accelerate the commercialization of its cuffless blood pressure monitoring technology. The company's strategic roadmap focuses on scaling its enterprise-level health solutions, ensuring that its biometric sensor platforms are integrated into a broader ecosystem of wearable devices. By prioritizing research and development, Valencell aims to refine its predictive analytics capabilities, thereby enhancing the accuracy and reliability of its health monitoring tools. As the digital health market continues to expand, Valencell's commitment to innovation and its strong patent moat provide a distinct competitive advantage, setting the stage for sustained long-term growth and deeper penetration into the global chronic disease management market.
See full Valencell company page
